Yayın:
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer

Sadeleştirilmiş öğe sayfası
dc.contributor.authorTurhal, Serdar
dc.contributor.authorMehmet Ali Nahit Sendur
dc.contributor.authorİrem Bilgetekin
dc.contributor.authorDuygu Bayır Garbioğlu
dc.contributor.authorJamshid Hamdard
dc.contributor.authorSinem Akbaş
dc.contributor.authorMutlu Hızal
dc.contributor.authorÇağatay Arslan
dc.contributor.authorAlper Sevinç
dc.contributor.authorAhmet Küçükarda
dc.contributor.authorDi̇lek Erdem
dc.contributor.authorSeda Kahraman
dc.contributor.authorEmre Çakır
dc.contributor.authorAykut Demirkıran
dc.contributor.authorSercan On
dc.contributor.authorİzzet Doğan
dc.contributor.authorAtike Pinar Erdogan
dc.contributor.authorSinan Koca
dc.contributor.authorP. Kubilay
dc.contributor.authorOrhan Önder Eren
dc.contributor.authorEbru Çılbır
dc.contributor.authorEmir Çelik
dc.contributor.authorMurat Araz
dc.contributor.authorDeniz Tataroglu Ozyukseler
dc.contributor.authorMahmut Emre Yildirim
dc.contributor.authorAykut Bahçeci
dc.contributor.authorHalil Taşkaynatan
dc.contributor.authorAbdilkerim Oyman
dc.contributor.authorGülhan Ipek Deniz
dc.contributor.authorSerkan Menekşe
dc.contributor.authorEngin Kut
dc.contributor.authorAhmet Gülmez
dc.contributor.authorAbdullah Sakin
dc.contributor.authorErdinç Nayır
dc.contributor.authorRamazan Acar
dc.contributor.authorErdem Şen
dc.contributor.authorAli̇ İnal
dc.contributor.authorSerdar Turhal
dc.contributor.authorAli Kaya
dc.contributor.authorSemra Paydaş
dc.contributor.authorDidem Taştekin
dc.contributor.authorİlhan Hacıbekiroğlu
dc.contributor.authorIrfan Cincin
dc.contributor.authorAhmet Bılıcı
dc.contributor.authorNil Molinas Mandel
dc.contributor.authorDidem Sener Dede
dc.contributor.authorMuhammed Bülent Akıncı
dc.contributor.authorBerna Öksüzoğlu
dc.contributor.authorDoğan Uncu
dc.contributor.authorBülent Yalçın
dc.contributor.authorMehmet Artaç
dc.contributor.orcid0000-0003-3155-8798
dc.contributor.orcid0000-0003-1154-5850
dc.contributor.orcid0000-0002-7197-211X
dc.contributor.orcid0000-0001-5147-4431
dc.contributor.orcid0000-0002-3783-7432
dc.contributor.orcid0000-0002-0499-8918
dc.contributor.orcid0000-0001-7399-2360
dc.contributor.orcid0000-0001-6495-6712
dc.contributor.orcid0000-0002-5328-6554
dc.contributor.orcid0000-0003-0411-8818
dc.contributor.orcid0000-0002-2842-4695
dc.contributor.orcid0000-0003-1018-1119
dc.contributor.orcid0000-0002-2263-005X
dc.contributor.orcid0000-0001-6397-8207
dc.contributor.orcid0000-0001-8440-3082
dc.contributor.orcid0000-0002-4632-9501
dc.contributor.orcid0000-0001-7921-5204
dc.contributor.orcid0000-0002-3671-6540
dc.contributor.orcid0000-0002-2291-7544
dc.contributor.orcid0000-0002-2134-2128
dc.contributor.orcid0000-0002-5328-5607
dc.contributor.orcid0000-0002-3353-344X
dc.contributor.orcid0000-0003-2538-8569
dc.contributor.orcid0000-0003-2348-7803
dc.contributor.orcid0000-0002-3094-899X
dc.contributor.orcid0000-0002-0690-2529
dc.contributor.orcid0000-0001-7182-6641
dc.contributor.orcid0000-0003-4642-3693
dc.contributor.orcid0000-0002-9522-9849
dc.contributor.orcid0000-0002-0333-7405
dc.contributor.orcid0000-0002-0443-6966
dc.contributor.orcid0000-0001-7575-9925
dc.contributor.orcid0000-0002-2756-8646
dc.contributor.orcid0000-0002-0929-3271
dc.contributor.orcid0000-0002-4431-8948
dc.contributor.orcid0000-0003-2335-3354
dc.date.accessioned2025-11-13T10:27:07Z
dc.date.issued2022-08-12
dc.identifier.doihttps://doi.org/10.4103/jcrt.jcrt_1104_21
dc.identifier.endpageS353
dc.identifier.issn0973-1482
dc.identifier.issueSuppl 2
dc.identifier.openalexW4291137685
dc.identifier.startpageS347
dc.identifier.urihttps://hdl.handle.net/11421/4191
dc.identifier.urihttps://doi.org/10.4103/jcrt.jcrt_1104_21
dc.identifier.volume18
dc.language.isoen
dc.relation.ispartofJournal of Cancer Research and Therapeutics
dc.rightsopenAccess
dc.subjectAflibercept
dc.subjectMedicine
dc.subjectFOLFIRI
dc.subjectIrinotecan
dc.subjectBevacizumab
dc.subjectInternal medicine
dc.subjectOncology
dc.subjectKRAS
dc.subjectRegimen
dc.subjectColorectal cancer
dc.subjectCapecitabine
dc.subjectProgression-free survival
dc.subjectOxaliplatin
dc.subjectSurgery
dc.subjectCancer
dc.subjectChemotherapy
dc.subject.sdg3
dc.titleEfficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5108484042

Dosyalar

Koleksiyonlar

Publications